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Introduction
Major depressive disorder (MDD) is common in
elderly patients, with an estimated prevalence of
about 3% (1). It is often associated with physical dis-
ability and a high mortality rate (2,3). Elderly
patients are more predisposed to depression than
younger patients because of concurrent medical dis-
orders, chronic pain, sadness secondary to life-cycle
issues and social isolation (4). These conditions
impair the quality of life in a number of ways, inclu-
ding social and vocational functioning, and emo-
tional and physical well-being.
A large 4-year prospective study suggested that
approximately 25% of patients ‡ 65 years with chro-
nic medical illness suffer from depressive symptoma-
tology (5). Substantial evidence supports the
increased prevalence of depression in several chronic
medical illnesses, including various forms of vascular
disease (cardiovascular, cerebrovascular or peripheral
vascular), diabetes mellitus and arthritis. Speciﬁcally,
patients with cardiovascular disease, diabetes mellitus
or arthritis appear to have approximately 2–3 times
the risk for depression (6–8).
Conversely, depression tends to worsen comorbid
medical illnesses and may lead to increased mortality.
Depression in patients following myocardial infarc-
tion (MI) is a risk factor for mortality at 6 months
of hospitalisation (9) and a signiﬁcant predictor of
18-month post-MI cardiac mortality (10). Another
study reported that depressive symptoms among
women with HIV are associated with HIV disease
progression (11). It has been found from the Systolic
Hypertension in the Elderly Programme that depres-
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MDD.
What’s known
Analyses of primary efﬁcacy data from this elderly
study have shown that duloxetine 60 mg/day
improved cognitive function. Duloxetine 60 mg/day
also produced signiﬁcant improvements vs. placebo
in the Geriatric Depression Scale and HAMD17 total
scores, as well as some pain measures.
What’s new
The present report investigates the impact of
medical comorbidity on the efﬁcacy of duloxetine in
the treatment of depression, improvement of
cognition, as well as quality of life and its
tolerability in elderly patients with major depressive
disorder.
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stroke, MI and death (12). Similarly, patients with
depression and comorbid diabetes mellitus have
higher risk for a poor adherence to diet and medica-
tion regimens, greater functional impairment and
higher healthcare costs than their non-depressed
counterparts (13).
Comorbidity of depression and medical illness in
elderly patients leads to increased morbidity and
mortality, as well as higher healthcare costs (14).
Therefore, there is a need for a safe, well-tolerated
and effective antidepressant in elderly patients with
MDD, particularly in those suffering from MDD
with chronic medical illness.
Duloxetine hydrochloride is an antidepressant that
inhibits both serotonin (5-HT) and norepinephrine
(NE) reuptake (15). The dual-acting mechanism of
duloxetine makes it particularly interesting in the
treatment of depression with cognitive impairment,
as imbalance or deﬁciency in either 5-HT or NE sys-
tems has been found to contribute to cognitive deﬁ-
cits (16,17). Duloxetine has been shown to treat
depression effectively in the elderly population on
the basis of pooled subgroup analyses of two previ-
ous duloxetine clinical trials in general populations
(18). To conﬁrm the efﬁcacy of duloxetine in elderly
patients with MDD, a multicentre, parallel, double-
blind, placebo-controlled study of 311 elderly
patients ‡ 65 years with MDD was conducted (19).
Analyses of primary efﬁcacy data from this elderly
patient study have shown that duloxetine 60 mg/day
improved cognitive function, as evidenced by signiﬁ-
cantly greater improvement in the composite cogni-
tive score vs. placebo. Duloxetine 60 mg/day also
showed signiﬁcant improvements vs. placebo in the
Geriatric Depression Scale (GDS) and 17-Item Ham-
ilton Depression Scale (HAMD17) total scores, as well
as some pain measures (19). The present report
investigates the impact of medical comorbidity on
the efﬁcacy of duloxetine in cognition, depression
and quality of life and its tolerability in elderly
patients with MDD.
Methods
Study design
This multicentre, randomised, double-blind, pla-
cebo-controlled study was conducted in elderly
patients with MDD. After a 1-week screening phase,
all patients entered a 1-week, double-blind, placebo
phase before being randomised to duloxetine
60 mg/day (n ¼ 207) or placebo (n ¼ 104) for
8 weeks. This was followed by a 1-week, double-
blind, discontinuation phase in which the dosage of
duloxetine was tapered to 30 mg/day for 4 days.
Patients, investigators and all other personnel
involved in the conduct of the study were blinded
to individual treatment assignments for the duration
of the study.
Patients
All patients in this study were ‡ 65 years of age and
met diagnostic criteria for MDD as deﬁned in the
Diagnostic and Statistical Manual of Mental Disor-
ders, 4th edition (DSM-IV) (20). The diagnosis was
conﬁrmed by the Mini International Neuropsychiat-
ric Interview (21), a standardised diagnostic inter-
view based on DSM-IV criteria. Baseline disease
severity was deﬁned by patients’ scores on the
HAMD17 (22). Patients were required to have:
HAMD17 total score ‡ 18 at visits 1 and 2, a Mini
Mental State Examination (MMSE) (23) score ‡ 20
with or without mild dementia and at least one pre-
vious episode of major depression. Patients with a
MMSE score of 20–23 were categorised as having
mild dementia, while those with a score of ‡ 24 were
categorised as having no dementia. Administration of
study drug and conduct of the study were in accord-
ance with the Declaration of Helsinki. Each patient
provided written informed consent prior to any
study procedures.
Patients were excluded for the following reasons:
current primary axis I diagnosis other than MDD or
mild dementia (including dysthymia or psychotic
depression); previous diagnosis of psychotic disorder;
organic mental disorder, moderate-to-severe dementia
or mental retardation diagnosis; serious or unstable
medical illness, psychological condition or clinically
signiﬁcant laboratory abnormality that, in the opinion
of the investigator, would compromise participation
in this study or be likely to lead to hospitalisation
during the course of the study; or ALT, AST or GGT
> 1.5 times upper limit of normal, based on Eli Lilly
and Company’s reference ranges (24).
Efﬁcacy and tolerability measures
The primary efﬁcacy measure was a prespeciﬁed
composite cognitive score based on four cognitive
tests: (i) Verbal Learning and Recall Test (VLRT),
adapted from the Rey Auditory Verbal Learning Test
(25,26); (ii) Symbol Digit Substitution Test (SDST);
(iii) 2-Digit Cancellation Test (2DCT) and (iv) Let-
ter-Number Sequencing Test (LNST). These partic-
ular tests were selected because they assess aspects of
cognition shown previously to be most impaired in
patients with depression, speciﬁcally verbal learning
and memory, attention, executive function and
working memory (27,28). Moreover, each of these
tests has been used extensively in clinical psycho-
pharmacology.
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HAMD17 total scores, HAMD17 response and remis-
sion, Visual Analogue Scale (VAS) for pain, Clinical
Global Impression-Severity (CGI-S), and the 36-Item
Short Form Health Survey (SF-36). HAMD17
response was deﬁned as a ‡ 50% decrease in the
HAMD17 total score from baseline to end-point.
Remission was deﬁned as a HAMD17 total score of
£ 7 at end-point. Tolerability measures included
adverse events (AEs) reported as the reason for dis-
continuation and treatment-emergent adverse events
(TEAEs).
The composite cognitive score, ranging from 0 to
51, was deﬁned as the sum of: (i) the average num-
ber of words recalled on the three learning trials of
the VLRT (score 0–15) and the number of words
recalled on the delayed recall test of the VLRT (score
0–15); (ii) the fraction of all possible targets correct
on the SDST (number correct divided by 133) multi-
plied by 7 (score 0–7); (iii) the number of targets
hit, minus the number incorrect, minus the number
of times the patients had to be reminded of the task,
divided by the possible number correct (40) on the
2DCT, multiplied by 7 (score 0–7, set to 0 if negat-
ive) and (iv) the total score on the LNST (0–21)
divided by 3 (score 0–7).
The GDS scale was developed as a basic screening
measure for elderly patients with MDD (29,30). The
VAS quantitatively measures overall pain, headache,
back pain, shoulder pain, pain interference with daily
activities and time in pain while awake (31).
Cognition measures and the SF-36 were recorded
once prior to randomisation and at the last visit of
the acute treatment phase. The GDS, HAMD17, CGI-
Severity and VAS were recorded once prior to rand-
omisation and at every visit of the acute treatment
phase.
Description of comorbidity
The medical comorbidity group included patients
with one or any of the following three categories of
illnesses: vascular (cardiovascular, cerebrovascular or
peripheral vascular) disease, diabetes mellitus or
arthritis. Medical comorbidities were recorded at
baseline to indicate the presence of any of the above
illness(es). Indications for comorbidity were based
on physical examination, previous diagnosis or
patient report.
Statistical analysis
All analyses were conducted on an intent-to-treat
basis, which is an analysis of the groups to which
patients are randomly assigned, even if the patient
did not take the assigned treatment, did not receive
the correct treatment or otherwise did not follow the
protocol. Some analyses were deﬁned a priori in the
protocol; others were post hoc. The term ‘signiﬁcant’
for treatment comparisons indicates statistical signiﬁ-
cance (two-sided p £ 0.05). No adjustments for mul-
tiple comparisons were made. Throughout this
manuscript, ‘mean’ refers to the raw mean unless the
least-squares (LS) mean is speciﬁed.
Unless otherwise speciﬁed, ‘baseline’ refers to the
last non-missing prerandomisation observation and
‘end-point’ refers to the last non-missing observation
during the treatment phase. Total scores (e.g. com-
posite cognitive score, GDS and HAMD17 total
scores) were considered to be missing if any of the
item scores were missing.
Changes in continuous efﬁcacy variables from
baseline to end-point, overall and within subgroups,
were analysed using a ﬁxed-effects analysis of covari-
ance (ANCOVA) model that included terms for
treatment, investigator and baseline score. This is
referred to as a mean change (MC) analysis. Categor-
ical measures, overall and within subgroups, were
analysed using Fisher’s exact test.
The consistency of the effect of duloxetine com-
pared with placebo in comorbidity subgroups, as
described in the protocol, was investigated for con-
tinuous variables by adding the subgroup and treat-
ment-by-subgroup interaction terms to the
ANCOVA model. Corresponding consistency analy-
ses for rates of HAMD17 response and remission
were performed using a logistic regression model
that included terms for treatment, subgroup and
treatment-by-subgroup. The consistency for rates of
AEs reported as the reason for discontinuation and
for TEAEs in patients with comorbidity and
without comorbidity were performed using the
Breslow-Day test, which assesses the signiﬁcance of
treatment differences in incidence rates between
subgroups. Interaction effects were tested at a 0.10
signiﬁcance level.
TEAEs were deﬁned as events that ﬁrst occurred
or worsened postrandomisation during the treatment
phase when compared with the maximum prerand-
omisation severity. AEs were reported using preferred
terms from the Medical Dictionary for Regulatory
Activities (MedDRA, MMSO, Reston, VA, USA),
version 7.0.
As speciﬁed in the protocol, 200 duloxetine- and
100 placebo-treated patients provided 80% power to
detect an effect size (difference between MCs in the
composite cognitive score divided by the common
standard deviation) of 0.35, using a 5%, two-sided
signiﬁcance level and assuming data were available
for analyses in 95% of patients. This reﬂects
the power of the study with regard to the primary
analysis.
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Patient characteristics
Baseline patient characteristics are summarised in
Table 1. Overall, 55.3% of the patients had arthritis,
14.8% had diabetes, 36.0% had vascular comorbidity
and 74.9% of patients had at least one of these comor-
bidities. As expected, mean age was higher in patients
with vascular comorbidity vs. without vascular comor-
bidity and VAS overall pain severity was higher in
patients with arthritis vs. without arthritis. Further-
more, patients with vascular comorbidity had more
previous episodes of MDD and longer duration of the
current episode of MDD; patients with diabetes had
higher mean weight, which is clinically relevant and
conﬁrms the validity of the sample. It is worth noting
that SF-36 physical component summary scores were
lower in patients from all subgroups with medical com-
orbidities, suggesting that a presence of medical comor-
bidity is associated with worsened patient-reported
physical well-being. Most of these characteristics for
speciﬁc comorbidity also were reﬂected in the compari-
sons between those with or without any comorbidity.
Efﬁcacy in cognitive measures (primary)
Figure 1 presents the MC from baseline in the com-
posite cognitive score for all randomised patients
and by subgroups based on presence or absence of
the comorbidities. Duloxetine signiﬁcantly improved
cognitive performance compared with placebo in all
randomised patients (1.95 vs. 0.76, p ¼ 0.013). Dul-
oxetine-treated patients showed signiﬁcantly greater
improvement compared with placebo-treated patients
in the composite cognitive score for patients having
any of the three medical comorbidities (2.15 vs. 0.60;
p ¼ 0.006). A signiﬁcant difference did not occur for
patients without a medical comorbidity (duloxetine,
1.38; placebo, 0.96; p ¼ 0.724). However, there were
no statistically signiﬁcant treatment-by-comorbidity
interactions for any comorbidity (p ¼ 0.266) or for
any of the individual comorbidities.
Efﬁcacy in depression measures
Results from the MC analyses of the depression efﬁc-
acy measures are shown in Figure 2A,B. Patients
treated with duloxetine had signiﬁcantly greater
improvement in both GDS and HAMD17 total scores
Table 1 Baseline patient characteristics by comorbidity
Any Arthritis Diabetes Vascular
No Yes No Yes No Yes No Yes
(n ¼ 78) (n ¼ 233) (n ¼ 139) (n ¼ 172) (n ¼ 265) (n ¼ 46) (n ¼ 199) (n ¼ 112)
Placebo: 26 78 49 55 93 11 60 44
Duloxetine: 52 155 90 117 172 35 139 68
Characteristics
Gender, female, n (%) 35 (44.9) 150 (64.4) 63 (45.3) 122 (70.9) 164 (61.9) 21 (45.7) 118 (59.3) 67 (59.8)
Age, years, mean (SD) 71.3 (5.3) 73.4 (5.7) 72.7 (5.6) 73.0 (5.8) 72.9 (5.8) 73.0 (5.1) 72.2 (5.7) 74.1 (5.5)
Age range, years 65–88 65–89 65–88 65–89 65–89 65–85 65–89 65–86
Weight, kg, mean (SD) 79.1 (17.4) 80.4 (18.4) 80.2 (16.1) 80.0 (19.6) 78.8 (18.0) 87.5 (17.5) 78.9 (18.0) 82.1 (18.2)
Ethnicity, n (%)
Caucasian 60 (76.9) 183 (78.5) 105 (75.5) 138 (80.2) 210 (79.2) 33 (71.7) 154 (77.4) 89 (79.5)
Hispanic 13 (16.7) 35 (15.0) 25 (18.0) 23 (13.4) 37 (14.0) 11 (23.9) 35 (17.6) 13 (11.6)
African descent 3 (3.8) 14 (6.0) 6 (4.3) 11 (6.4) 15 (5.7) 2 (4.3) 8 (4.0) 9 (8.0)
Western Asian 1 (1.3) 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.5) 0 (0.0)
Other 1 (1.3) 1 (0.4) 2 (1.4) 0 (0.0) 2 (0.8) 0 (0.0) 1 (0.5) 1 (0.9)
Psychiatric proﬁle, mean (SD)*
Composite Cognitive Score 23.9 (8.0) 22.5 (6.6) 22.6 (7.3) 23.0 (6.7) 23.2 (7.1) 21.1 (6.2) 23.4 (7.5) 21.9 (5.8)
HAMD17 total (visit 1) 22.5 (3.4) 22.2 (3.8) 22.2 (3.6) 22.3 (3.8) 22.3 (3.7) 21.9 (3.8) 22.5 (3.8) 21.7 (3.4)
HAMD17 total (randomisation) 19.2 (5.0) 18.7 (4.6) 19.0 (4.7) 18.7 (4.7) 18.8 (4.7) 19.4 (4.7) 18.9 (5.0) 18.7 (4.2)
GDS total 17.5 (7.5) 17.7 (7.0) 17.4 (7.1) 17.9 (7.1) 17.6 (7.2) 17.9 (6.8) 18.1 (7.1) 16.8 (7.1)
Duration of current episode, weeks 59.8 (89.3) 54.3 (85.3) 61.8 (101.5) 50.7 (71.4) 56.9 (88.6) 48.8 (71.6) 50.3 (70.0) 65.2 (108.7)
Number of previous episodes 4.5 (6.3) 5.8 (16.4) 5.9 (17.7) 5.1 (11.2) 5.3 (13.9) 6.4 (17.8) 4.7 (9.9) 6.7 (20.3)
VAS overall pain severity 21.9 (21.6) 34.4 (27.6) 22.5 (21.7) 38.3 (28.3) 30.6 (26.3) 35.0 (28.9) 32.9 (27.7) 28.3 (24.7)
SF-36 physical component 46.0 (11.2) 40.0 (10.3) 44.6 (11.1) 39.0 (9.8) 42.3 (10.8) 37.3 (9.9) 42.5 (10.7) 39.9 (10.9)
SF-36 mental component 31.6 (12.3) 32.4 (10.5) 32.3 (12.0) 32.2 (10.1) 32.1 (10.8) 33.0 (12.0) 31.7 (11.1) 33.1 (10.8)
*Total sample sizes for variables shown range from 304 to 311.
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no statistically signiﬁcant treatment-by-comorbidity
interactions for either GDS or HAMD17 total scores.
Moreover, CGI-S ﬁndings were consistent with ﬁnd-
ings for GDS and HAMD17 total scores (data not
shown).
Duloxetine-treated patients had signiﬁcantly
greater rates of response (37.3% vs. 18.6%,
p < 0.001) and remission (27.4% vs. 14.7%, p ¼
0.014) compared with placebo-treated patients. There
were no statistically signiﬁcant treatment-by-comor-
bidity interactions for either response or remission
rate, suggesting that comorbidity status did not affect
the treatment effect of duloxetine in achieving
response or remission.
Efﬁcacy in pain measures
In all randomised patients, there was a signiﬁcantly
greater improvement in VAS for back pain ()5.72
vs. 1.41, p ¼ 0.008) and time in pain while awake
()6.36 vs. 0.99, p ¼ 0.028) for duloxetine compared
with placebo. The treatment difference for other pain
measures, including overall pain, headache, shoulder
pain and pain interference with daily activities, was
not statistically signiﬁcant. There were no statistically
signiﬁcant treatment-by-comorbidity interactions for
headache and shoulder pain. However, there were
statistically signiﬁcant treatment-by-comorbidity
interactions: overall pain for the arthritis (interac-
tion, p ¼ 0.037; with arthritis, duloxetine, )7.97;
placebo, 1.29, p ¼ 0.052; without arthritis, duloxe-
tine, )1.27; placebo, )6.13, p ¼ 0.241) and vascular
(interaction, p ¼ 0.077; with vascular disease, dul-
oxetine, 1.81; placebo, 11.59, p ¼ 0.059; without
vascular disease, duloxetine, )7.79; placebo, )7.13,
p ¼ 0.868) comorbidities; interference with daily
activities (interaction, p ¼ 0.057; with arthritis, dul-
oxetine, )4.85; placebo, 3.52, p ¼ 0.067; without
arthritis, duloxetine, )1.53; placebo, )6.75, p ¼
0.198) and back pain (interaction, p ¼ 0.001; with
arthritis, duloxetine, )8.79; placebo, 5.96, p < 0.001;
without arthritis, duloxetine, )2.08; placebo, )6.64,
p ¼ 0.227) for arthritis comorbidity; and time in
pain while awake for vascular comorbidity (inter-
action, p ¼ 0.090; with vascular disease, duloxetine,
)2.05; placebo, 10.01, p ¼ 0.048; without vascular
disease, duloxetine, )8.24; placebo, )5.30, p ¼
0.477). To each of these ﬁve signiﬁcant interactions,
duloxetine was more effective compared with placebo
in patients with the comorbidity when compared
with those without the comorbidity.
Efﬁcacy in SF-36 improvement
In all randomised patients, there was a signiﬁcantly
greater improvement with duloxetine treatment com-
pared with placebo in the SF-36 physical component
summary (0.61 vs. )1.14, p ¼ 0.047), but not for the
SF-36 mental component summary (8.33 vs. 6.18,
p ¼ 0.117). There were no statistically signiﬁcant
treatment-by-comorbidity interactions for the SF-36
physical component summary (Figure 3). However,
there was a signiﬁcant treatment-by-comorbidity
interaction for the SF-36 mental component sum-
mary with respect to vascular comorbidity (p ¼
0.077); a statistically signiﬁcant beneﬁt of duloxetine
over placebo was shown for patients with vascular
comorbidity (8.91 vs. 3.04, p ¼ 0.015), but not for
those without vascular comorbidity (8.17 vs. 7.85,
Figure 1 Effects of duloxetine compared with placebo on composite cognitive score: mean change analysis in all
randomised patients and in baseline comorbidity subgroups
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ment-by-comorbidity interaction (p ¼ 0.044) for
physical functioning for vascular comorbidity (with
vascular disease, duloxetine, 1.96; placebo, 4.66, p ¼
0.519; without vascular disease, duloxetine, 4.76; pla-
cebo, )3.60, p ¼ 0.005) and for social functioning
(p ¼ 0.016) for arthritis comorbidity (with arthritis,
duloxetine, 16.58; placebo, 4.64, p ¼ 0.004; without
arthritis, duloxetine, 11.62; placebo, 15.44, p ¼
0.432).
Tolerability
Tolerability was analysed in all randomised patients
and by any comorbidity subgroups. Overall discon-
tinuation rates for any reason did not signiﬁcantly
differ between the duloxetine and placebo groups
(21.7% vs. 23.1%, p ¼ 0.775). However, the rate of
discontinuation caused by lack of efﬁcacy was signi-
ﬁcantly greater among placebo-treated patients than
duloxetine-treated patients (9.6% vs. 2.9%; p ¼
0.026). The incidence of discontinuation caused by
AEs was similar in both treatment groups (9.7% vs.
8.7%, p ¼ 0.839). Nausea was the only AE leading
to discontinuation that occurred at a statistically
signiﬁcantly different rate in duloxetine-than in pla-
cebo-treated patients, and the rate of discontinu-
ation caused by this AE was lower for duloxetine
than for placebo (0.5% vs. 3.8%, p ¼ 0.044). There
were no signiﬁcant treatment-by-comorbidity inter-
actions for incidences of discontinuation because of
an AE.
TEAEs for which the incidence among duloxetine-
treated patients was at least 5.0% and twice the pla-
cebo rate are presented in Table 2. The incidence of
at least one TEAE was similar for duloxetine and pla-
cebo (70.0% vs. 64.4%, p ¼ 0.367) in overall
(A)
(B)
Figure 2 (A) Effects of duloxetine compared with placebo on GDS total score: mean change analysis in all randomised
patients and in baseline comorbidity subgroups. (B) Effects of duloxetine compared with placebo on HAMD17 total score:
mean change analysis in all randomised patients and in baseline comorbidity subgroups
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ment-by-comorbidity interaction (p ¼ 0.030) for any
comorbidity. For patients with any comorbidity, the
incidences were similar for the two treatment groups,
but for patients with no comorbidity, the incidence
was higher for duloxetine than for placebo (76.9%
vs. 50.0%; p ¼ 0.022). Of these TEAEs, those occur-
ring signiﬁcantly more frequently for duloxetine than
for placebo in overall patients were dry mouth
(14.5% vs. 1.9%; p < 0.001), nausea (12.6% vs.
3.8%; p ¼ 0.014) and diarrhoea (8.2% vs. 1.9%;
p ¼ 0.042). There was no statistically signiﬁcant
treatment-by-comorbidity interaction for the inci-
dence of any of the common TEAEs.
Discussion
These results support the efﬁcacy and tolerability of
duloxetine in the treatment of elderly patients with
MDD with or without common comorbid medical
conditions. Overall, duloxetine-treated patients dem-
onstrated signiﬁcantly greater improvement com-
pared with placebo-treated patients on outcome
measures that included the composite cognitive
score, depression severity measures and several of the
SF-36 and VAS measures. Few signiﬁcant treatment-
by-comorbidity subgroup interactions occurred for
these efﬁcacy variables, or for AEs reported as the
reason for discontinuation or common TEAEs, sug-
gesting that the efﬁcacy and tolerability of duloxetine
in the treatment of depression in elderly patients
were not largely affected by comorbidity status. Spe-
ciﬁcally, the results regarding the impact of comor-
bid medical illness on treatment outcomes in MDD
were consistent regardless of whether the outcomes
were measured with the GDS, the HAMD17
or CGI-S.
This study reafﬁrms the high prevalence of med-
ical comorbidity in patients with late-life depression
because nearly 75% of patients participating in the
study met criteria for the presence of medical comor-
bidity. This proportion may be an underestimate, as
patients with unstable acute medical illness were
excluded from the study. Moreover, we measured
only three common medical comorbidities; a higher
prevalence of comorbidities likely would have been
measured if more medical illnesses were recorded.
Most of the ﬁndings in patient baseline characteris-
tics were as expected; for instance, mean age was
higher in patients with vascular comorbidity and
VAS overall pain severity was higher in patients with
arthritis. The fact that patients with vascular comor-
bidity had more previous episodes and longer dur-
ation of current episode of MDD may be attributed
to certain vascular-related factors contributing to
depression, including brain damage from infarcts or
microvascular effects (6). Such factors are in line
with the notion that physical illness and depression
tend to have mutually worsening effects.
Although cognitive deﬁcits in patients with MDD,
especially the elderly patients, have been demonstra-
ted in many studies (27), antidepressant drugs do
not routinely improve cognition in such patients
(32,33). Follow-up studies of patients treated for
MDD have shown that some patients demonstrate
poor performance on cognitive tests even after treat-
ment (34). In the present study, duloxetine-treated
patients demonstrated similar improvement on the
Figure 3 Effects of duloxetine compared with placebo on SF-36 Physical Component Summary: mean change analysis in
all randomised patients and in baseline comorbidity subgroups
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bid illness. However, even though the treatment-by-
subgroup interaction was not signiﬁcant, patients
with any of the three comorbid illnesses and treated
with duloxetine showed a signiﬁcantly greater
improvement on the composite cognitive score com-
pared with the placebo group. In the subgroup with-
out a comorbid illness, duloxetine did not show
signiﬁcantly greater improvement than did placebo.
Although the explanation for this lesser improvement
in the group without a comorbid illness is unknown,
it could be an artifact as a result of the relatively
small number of patients in that subgroup. Neverthe-
less, the augmenting effect of duloxetine on 5-HT
and NE activity may make it particularly beneﬁcial
in treating the cognitive deﬁcits associated with
depression as imbalance or deﬁciency in either 5-HT
or NE neurotransmission has been found to contrib-
ute to cognitive deﬁcits (16,17). Treatment of depres-
sion with tricyclics, such as imipramine, has been
found to improve cognitive function despite the det-
rimental anticholinergic effects (35).
The comorbidity of pain and depression in elderly
patients is of special signiﬁcance when considering
the high prevalence of pain in this age group (36,37).
A direct relationship between pain severity and
depression has been identiﬁed in elderly patients
with chronic pain (37). In the present analyses,
duloxetine demonstrated statistically signiﬁcant
improvements in two of the six pain measures: the
VAS for back pain and time in pain while awake.
These ﬁndings suggest that duloxetine may be effect-
ive in relieving pain caused by chronic conditions,
including arthritis and vascular disease. Duloxetine
has been shown to be effective in the management of
diabetic peripheral neuropathic pain (38,39) and in
improving painful physical symptoms independent of
improvement of depression severity in younger
MDD populations (40). However, patients enrolled
in this study were not selected speciﬁcally for pain
and the pain reported was generally not severe. It is
possible that more or less robust efﬁcacy for duloxe-
tine might be observed in patients with depression
who have a higher baseline pain severity.
Table 2 Treatment-emergent adverse events, overall and by any comorbidity subgroup
Event (‡ 5% and twice
rate of placebo overall)
Comorbidity
stratum
Placebo
Duloxetine
60 mg QD
Treatment
p-value*
Treatment-by-subgroup
p-value N n (%) N n (%)
Patients with ‡ 1 TEAEs Overall 104 67 (64.4) 207 145 (70.0) 0.367 –
Yes 78 54 (69.2) 155 105 (67.7) 0.882 0.030
No 26 13 (50.0) 52 40 (76.9) 0.022
Dry mouth Overall 104 2 (1.9) 207 30 (14.5) < 0.001 –
Yes 78 2 (2.6) 155 23 (14.8) 0.003 0.440
No 26 0 (0.0) 52 7 (13.5) 0.088
Nausea Overall 104 4 (3.8) 207 26 (12.6) 0.014 –
Yes 78 3 (3.8) 155 19 (12.3) 0.055 0.933
No 26 1 (3.8) 52 7 (13.5) 0.257
Constipation Overall 104 5 (4.8) 207 21 (10.1) 0.131 –
Yes 78 4 (5.1) 155 12 (7.7) 0.588 0.311
No 26 1 (3.8) 52 9 (17.3) 0.151
Dizziness Overall 104 3 (2.9) 207 17 (8.2) 0.087 –
Yes 78 3 (3.8) 155 13 (8.4) 0.275 0.345
No 26 0 (0.0) 52 4 (7.7) 0.295
Diarrhoea Overall 104 2 (1.9) 207 17 (8.2) 0.042 –
Yes 78 2 (2.6) 155 12 (7.7) 0.150 0.366
No 26 0 (0.0) 52 5 (9.6) 0.163
Fatigue Overall 104 3 (2.9) 207 13 (6.3) 0.279 –
Yes 78 1 (1.3) 155 10 (6.5) 0.105 0.135
No 26 2 (7.7) 52 3 (5.8) 1.000
Somnolence Overall 104 1 (1.0) 207 11 (5.3) 0.067 –
Yes 78 1 (1.3) 155 7 (4.5) 0.274 0.455
No 26 0 (0.0) 52 4 (7.7) 0.295
*Signiﬁcant (p £ 0.05) within-stratum treatment comparison p-values are bolded if the treatment-by-subgroup p-value is statistically signiﬁcant (p £ 0.10).
Signiﬁcant (p £ 0.10) treatment-by-subgroup p-values are bolded.
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acute treatment studies of antidepressants, including
SSRIs, in medically ill patients with depression (41–
45). A review of 18 studies in mostly non-elderly
patients with depression and having at least one
physical disorder found that antidepressant treatment
was signiﬁcantly better than placebo in improving
depressive symptoms (42). In an 8-week study, older
patients treated with sertraline had similar responses
on the HAMD17 total score, CGI-S and CGI-I whe-
ther they had a comorbid medical illness or not (41).
In a study by Small et al. (45), geriatric patients with
major depression and with none, 1, 2, 3, 4 or ‡ 5
chronic physical illnesses were treated with ﬂuoxetine
20 mg/day or placebo for 6 weeks. The analyses
showed that the number of chronic illnesses did not
have an inﬂuence on treatment outcomes. One out-
come of interest from that study was the ﬁnding that
patients with a greater number of illnesses had a
greater response to ﬂuoxetine, whereas the opposite
was found with the placebo group, although the total
number of patients was somewhat small in the sub-
group with no chronic illnesses (N ¼ 73). A similar
ﬁnding was found with elderly patients with vascular
illnesses treated with sertraline (44). In a pooled ana-
lysis of two studies, patients were placed into three
groups: with hypertension, with vascular illness and
no hypertension, and no hypertension or cardiovas-
cular illness. The patients in the ﬁrst two groups
showed a consistently greater percentage of respond-
ers on the HAMD and CGI-I compared with the
third group.
In the present study, the absolute response and
remission rates were relatively low, which may be
attributed to the short 8-week study duration, as well
as the ﬁxed dosing schedule. Nevertheless, the relat-
ive advantages of duloxetine in response and remis-
sion rates were convincing, as evidenced by the fact
that they were twice the placebo rates and the differ-
ences were statistically signiﬁcant. In general, depres-
sion trials in the elderly patients are more difﬁcult to
show positive efﬁcacy results for active treatments
over placebo than do trials in the general population
(46). In a recent placebo-controlled study of ﬂuoxe-
tine and venlafaxine in patients ‡ 65 years with
MDD, there were no signiﬁcant differences among
the three treatment groups in the change of
HAMD21, MADRS or CGI scores, and the difference
in the proportion of remitters at the last on-therapy
visit was not statistically signiﬁcant (47). Similarly, in
a group of community-dwelling elderly patients
‡ 75 years with depression, citalopram was not more
effective than placebo for the treatment of depression
(48). However, in two larger studies in patients
‡ 60 years with depression, sertraline or ﬂuoxetine
was more effective than placebo (41,49). The remis-
sion rates in these studies were generally low, and
the differences between treatment groups were small
(20–35% for active treatments, 18–33% for placebo).
Duloxetine was well tolerated in patients with
medical comorbidity as well as in patients with no
medical comorbidity. More importantly, common
TEAEs and discontinuation caused by AEs were
comparable to those seen in younger, more general
populations receiving duloxetine (50). This is also in
line with what has been found with the SSRI sertr-
aline (41). A study of patients with late-life depres-
sion and having vascular disease, diabetes mellitus or
arthritis actually had a lower percentage of patients
experiencing the most common TEAEs than did
patients with no comorbid illnesses (41). In addition,
the percentage of patients discontinuing for any rea-
son, or speciﬁcally for AEs, were also lower in the
comorbid illness group. In the pooled analysis by
Krishnan et al. (44), there were also no differences
between the groups with comorbid illness compared
with the group with no comorbid illness in rates of
TEAEs and in discontinuation caused by TEAEs.
A number of limitations should be kept in mind
when evaluating the results of this study. First, the
study excluded patients with acute and unstable
medical conditions that are common among elderly
populations. The 8-week study duration of the trial
may be relatively short for a study in elderly patients.
Roose and Sackeim (51) have suggested that a mini-
mum of 12-week duration may be necessary to iden-
tify response or remission. Patients had limited-dose
ﬂexibility during the study, which may not be typical
of clinical practice for an elderly population. Comor-
bid medical conditions could also be based on med-
ical histories and patient report rather than a
diagnosis by a physician during the physical exam-
ination. Finally, the number of patients was relatively
small in the diabetes group.
In conclusion, results from this placebo-controlled
trial support the hypothesis that duloxetine is effect-
ive and well tolerated in treating elderly patients with
MDD. The duloxetine vs. placebo treatment effect on
cognition, depression and quality-of-life in elderly
patients with MDD was not largely affected by the
presence or absence of one or more of the three
medical comorbidities (vascular disease, diabetes and
arthritis) that frequently occur in the elderly popula-
tion.
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